Enfusion, Inc. (NYSE:ENFN) Receives $9.33 Consensus Target Price from Analysts

Enfusion, Inc. (NYSE:ENFN) has been assigned an average recommendation of “Reduce” from the six analysts that are covering the company, Marketbeat.com reports. Three research analysts have rated the stock with a sell rating, two have issued a hold rating and one has given a buy rating to the company. The average 1-year price target among analysts that have covered the stock in the last year is $9.33.

Several research analysts have recently weighed in on ENFN shares. JPMorgan Chase & Co. cut shares of Enfusion from a “neutral” rating to an “underweight” rating and reduced their price target for the company from $11.00 to $9.00 in a report on Tuesday, January 30th. Bank of America upped their target price on shares of Enfusion from $8.00 to $9.00 and gave the stock an “underperform” rating in a research note on Wednesday, March 13th. Finally, The Goldman Sachs Group cut Enfusion from a “neutral” rating to a “sell” rating and lowered their target price for the stock from $9.00 to $8.00 in a report on Wednesday, February 28th.

Enfusion Trading Down 5.0 %

ENFN stock opened at $9.28 on Tuesday. Enfusion has a 1-year low of $7.37 and a 1-year high of $11.56. The firm has a market cap of $1.19 billion, a PE ratio of 116.01, a P/E/G ratio of 2.79 and a beta of 0.97. The business’s 50-day moving average price is $9.22 and its two-hundred day moving average price is $9.17.

Enfusion (NYSE:ENFN) last released its quarterly earnings data on Tuesday, March 12th. The company reported $0.01 earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.02). Enfusion had a net margin of 3.45% and a return on equity of 10.30%. The business had revenue of $46.49 million for the quarter, compared to the consensus estimate of $45.56 million. On average, analysts forecast that Enfusion will post 0.07 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the business. Bleakley Financial Group LLC acquired a new stake in Enfusion in the 1st quarter valued at $176,000. Susquehanna Fundamental Investments LLC bought a new stake in Enfusion during the first quarter worth about $122,000. Swiss National Bank boosted its position in Enfusion by 20.0% during the first quarter. Swiss National Bank now owns 69,700 shares of the company’s stock valued at $645,000 after purchasing an additional 11,600 shares during the last quarter. Allspring Global Investments Holdings LLC bought a new position in Enfusion in the first quarter valued at approximately $44,000. Finally, Principal Financial Group Inc. bought a new position in Enfusion in the first quarter valued at approximately $452,000. Institutional investors and hedge funds own 81.05% of the company’s stock.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.